FDA seeks public opinion regarding NARMS 2026-2030 strategic plan
Jan. 15, 2025
The Food and Drug Administration (FDA) has published a request for comments asking for input that could potentially be included in the National Antimicrobial Resistance Monitoring System (NARMS) 2026-2030 Strategic Plan.
Specifically, they are looking for comments on “new opportunities” and “emergent monitoring needs,” according to FDA’s announcement. The NARMS “tracks changes in the antimicrobial susceptibility of enteric (intestinal) bacteria found in ill people (CDC), retail meats (FDA), and food animals (USDA) in the United States.”
The comment period will be open until March 26. A meeting will be held in the spring to discuss the comments received.
